Allogene Therapeutics, Inc.
ALLODrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Q3 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How ALLO's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ALLO-647 | Phase 2 | Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Allogene Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Allogene Therapeutics, Inc.'s (ALLO) pipeline across Phase 2. Its lead program is ALLO-647 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Allogene Therapeutics, Inc.'s next FDA catalyst?→
Allogene Therapeutics, Inc.'s (ALLO) next tracked catalyst is a Phase 2 expected August 24, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ALLO biotech catalysts?→
Add ALLO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Allogene Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.